Genetic Modulation of Oral Anticoagulation with Warfarin

Summary

Cytochrome P450 CYP2C9 gene variants have been associated with hyperresponsiveness to small doses of warfarin and a higher bleeding complication rate. The aim of this study was to investigate whether CYP2C9 gene variants affect doses of drug prescribed to acquire the target anticoagulation intensity and the occurence of bleeding complications. In a cohort of 180 patients followed up at one specialized clinic from the start of the anticoagulation with warfarin, we have investigated whether CYP2C9 gene variants have affected doses of drug prescribed to acquire the target anticoagulation intensity and the incidence of bleeding complications.

The adjusted dose required of warfarin was higher among patients with the CYP2C9*1 haplotype (5.6 mg) than those of patients carrying the CYP2C9*2 (4.7 mg; p = 0.007, Scheffé’s test) or the CYP2C9*3 haplotype (4.0 mg; p <0.001, Scheffé’s test). The occurrence of bleeding complications was more frequent among patients with the CYP2C9*2 and/or the CYP2C9*3 haplotype than in carriers of the CYP2C9*1 haplotype (OR: 2.57; 95% CI: 1.16–5.73). An interaction between the presence of local bleeding sources and the CYP2C9*2 and/or the CYP2C9*3 haplotype was observed (p <0.001). Patients with both local sites of potential bleeding and CYP2C9*2 and/or the CYP2C9*3 haplotype had the higher estimated risk of bleeding (OR: 12.81; 95% CI: 2.86–57.26).

CYP2C9 gene variants modulate the anticoagulant effect of the dose of warfarin prescribed. The incidence of bleeding complications in CYP2C9*2 and CYP2C9*3 carriers was significantly higher than that in noncarriers and interacted with the presence of local bleeding sources.

Key words

Warfarin - 450 CYP2C9 - polymorphisms - dose requirement - bleeding

• References

• 1 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Lärfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H, Viering S, Nordlander S, Leijd B, Jönsson KA, Hjorth M, Linder O, Boberg J. and the Duration of Anticoagulation Trial Study Group. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-5.
• 2 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three month of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
• 3 Hirsh J. The optimal duration of anticoagulation therapy for venous thromboembolism. N Engl J Med 1995; 332: 1710-1.
• 4 Fihn SD, Mcdonell M, Martin D, Henikoff J, Vernmess D, Kent D, White RH. Risk factors for complications of chronic anticoagulation A multicentre study. Ann Intern Med 1993; 118: 511-20.
• 5 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding-clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-28.
• 6 Levine MN, Hirsh J, Landefeld CS, Raskob G. Haemorrhagic complications of anticoagulant treatment. Chest 1992; 102 (suppl) 352-63.
• 7 van der Meer FJM, Rosendaal FR, Vanderbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy An analysis of risk factors. Arch Intern Med 1993; 153: 1557-62.
• 8 Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto C, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment An inception-cohort, prospective collaborative study. Lancet 1996; 348: 423-9.
• 9 Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. for The National Consortium of Anticoagulation Clinics. The risk for and the severity of bleeding complications in elderly patients treated with warfarin. Ann Int Med 1996; 124: 970-9.
• 10 Rettie AE, Korzekwa KR, Kunze KL, Lawrence RB, Eddy AC, Aoyama T, Gelboln HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P450 A role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 1992; 05: 54-9.
• 11 Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 06: 429-39.
• 12 Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired S-warfarin metabolismcalyzed by R144C allelic variant of CYP2C9. Pharmacogenetics 1994; 04: 39-42.
• 13 Steward DJ, Haining RL, Henne KR, Davids G, Rushmore TH, Trager WF, Rettie AE. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 07: 361-7.
• 14 Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphism in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1998; 353: 717-9.
• 15 Margaglione M, Brancaccio V, Giuliani N, D’Andrea G, Cappucci G, Iannaccone L, Vecchione G, Grandone E, Di Minno G. Increased risk of venous thrombosis in carriers of the prothrombin A²⁰²¹⁰ gene variant. Ann Intern Med 1998; 129: 89-93.
• 16 Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 1995; 108 (suppl) 231-46.
• 17 Hull JH, Murray WJ, Brown HS, Williams BO, Chi SL, Kock GG. Potential anticoagulant drug interactions in ambulatory patients. Clin Pharmacol Ther 1978; 24: 644-9.